All News

Reviewing Erlotinib/Binimetinib Combo in EGFR+ or KRAS+ NSCLC

June 30, 2022

Andreas Saltos, MD, discusses the key takeaways of the phase 1/1b clinical trial exploring the use of binimetinib plus erlotinib in patients with non–small cell lung cancer harboring either KRAS or EGFR mutations.

Behind the FDA Approval: Liso-Cel for R/R Large B-Cell Lymphoma

June 30, 2022

In an interview with Targeted Oncology, Manali Kamdar, discussed the recent FDA approval of lisocabtagene maraleucel for the treatment of patients with relapsed or refractory large B-cell lymphoma, and how community oncologists should approach patient referrals and post-treatment care.

FDA Grants Breakthrough Therapy Designation to Talquetamab for R/R Myeloma

June 29, 2022

The FDA has granted breakthrough therapy designation to talquetamab for the treatment of previously-treated adult patients with relapsed or refractory multiple myeloma based on positive results from the phase 1/2 MonumenTAL-1 study.